ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company s lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion VMA . The MAA for ocriplasmin has been accepted for review in Europe and the BLA has been re submitted in the U.S. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.
Quote | Oxurion NV (OTCMKTS:TBGNF)
Last: | $0.17 |
---|---|
Change Percent: | 0.0% |
Open: | $0.17 |
Close: | $0.17 |
High: | $0.17 |
Low: | $0.17 |
Volume: | 2,500 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Oxurion NV (OTCMKTS:TBGNF)
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The...
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program Eleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates ...
Message Board Posts | Oxurion NV (OTCMKTS:TBGNF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Thromboogenics Nv (TBGNF) Headlines ThromboGenics Acquires Exclusive Rights fr | Stock_Tracker | investorshangout | 03/11/2014 8:44:16 PM |
chartguy89: TBGNF 28.45 Stock Charts $TBGNF 1 Month Chart | chartguy89 | investorshangout | 03/10/2014 8:20:36 AM |
chartguy89: TBGNF Stock Charts Last: +0.50 Saturday, March 1, 2014 at 10:41:44 PM $TBGNF 1 M | chartguy89 | investorshangout | 03/02/2014 3:41:55 AM |
News, Short Squeeze, Breakout and More Instantly...
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The...
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program Eleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates ...
Postponement Annual Shareholders Meeting - Amendment financial calendar Leuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding its financial c...